Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies
The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B‐C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear pr...
Gespeichert in:
| Veröffentlicht in: | Liver international 2020-08, Vol.40 (8), p.1865-1871 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1871 |
|---|---|
| container_issue | 8 |
| container_start_page | 1865 |
| container_title | Liver international |
| container_volume | 40 |
| creator | Beaumont, Elodie Joël Clément, Benoit Guérin, Vanessa Chopin, Lucie Roch, Emmanuelle Gomez‐Escobar, Elsa Roingeard, Philippe |
| description | The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B‐C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV‐HCV bivalent vaccine‐bearing genotype 1a HCV envelopes can induce neutralizing antibodies against this genotype, but is less effective against other genotypes. We show here, in a small animal model, that the use of a set of vaccine particles harbouring envelopes from different HCV genotypes in various association strategies can induce broad neutralizing protection or an optimized protection against a particular genotype prevalent in a given region, such as genotype 4 in Egypt. This vaccine could help to control the hepatitis C epidemic worldwide. |
| doi_str_mv | 10.1111/liv.14541 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04112891v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2425718924</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4221-eb9757269b8e65ce7cd7c782777ce797d315dfacbdbd819750370a8b77730e6d3</originalsourceid><addsrcrecordid>eNp1kc1uEzEUhS0EoqWw4AWQJTawSOu_iWeWbQSkUhAbyNbyz03ryhkH2xOYrrphzzPyJDhNCRIS3vja99M59j0IvaTklNZ1Fvz2lIpG0EfomArZTjjj9PGhZvwIPcv5hhDadQ19io44E03bEHmMfnz0331_hTc6FW8DZLxKcY23Ovk4ZDyfLfEV9LGMm9ryvU2gc63KNeD5xfLX3c8dsdXW-h6wNj74MuISMQRvfcEmRe3CiG2KOVe6h6EkHfztzlP3xZvoPOTn6MlKhwwvHvYT9OX9u8-z-WTx6cPl7HwxsYIxOgHTyUayaWdamDYWpHXSypZJKeuhk47Txq20Nc64llaWcEl0a2qfE5g6foLe7nWvdVCb5Nc6jSpqr-bnC7W7I4JS1nZ0Syv7Zs9uUvw6QC5q7bOFEHQPdTSKCSI5FdWloq__QW_ikPr6k0qxRtK2Y-Kv-f0wEqwOL6BE7XJUNUd1n2NlXz0oDmYN7kD-Ca4CZ3vgmw8w_l9JLS6Xe8nfsc2pVw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425718924</pqid></control><display><type>article</type><title>Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Beaumont, Elodie ; Joël Clément, Benoit ; Guérin, Vanessa ; Chopin, Lucie ; Roch, Emmanuelle ; Gomez‐Escobar, Elsa ; Roingeard, Philippe</creator><creatorcontrib>Beaumont, Elodie ; Joël Clément, Benoit ; Guérin, Vanessa ; Chopin, Lucie ; Roch, Emmanuelle ; Gomez‐Escobar, Elsa ; Roingeard, Philippe</creatorcontrib><description>The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B‐C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV‐HCV bivalent vaccine‐bearing genotype 1a HCV envelopes can induce neutralizing antibodies against this genotype, but is less effective against other genotypes. We show here, in a small animal model, that the use of a set of vaccine particles harbouring envelopes from different HCV genotypes in various association strategies can induce broad neutralizing protection or an optimized protection against a particular genotype prevalent in a given region, such as genotype 4 in Egypt. This vaccine could help to control the hepatitis C epidemic worldwide.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.14541</identifier><identifier>PMID: 32458507</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Animal models ; Antibodies ; Disease control ; Envelopes ; Epidemics ; Genotype & phenotype ; Genotypes ; HCV genetic variability ; Hepatitis ; Hepatitis B ; hepatitis B virus ; Hepatitis C ; hepatitis C virus ; Life Sciences ; Neutralizing ; neutralizing antibodies ; prophylactic vaccine ; subviral envelope particles ; Vaccines ; Viruses</subject><ispartof>Liver international, 2020-08, Vol.40 (8), p.1865-1871</ispartof><rights>2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>This article is protected by copyright. All rights reserved.</rights><rights>2020 John Wiley & Sons A/S</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4221-eb9757269b8e65ce7cd7c782777ce797d315dfacbdbd819750370a8b77730e6d3</citedby><cites>FETCH-LOGICAL-c4221-eb9757269b8e65ce7cd7c782777ce797d315dfacbdbd819750370a8b77730e6d3</cites><orcidid>0000-0001-9131-3341</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.14541$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.14541$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32458507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-tours.hal.science/hal-04112891$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Beaumont, Elodie</creatorcontrib><creatorcontrib>Joël Clément, Benoit</creatorcontrib><creatorcontrib>Guérin, Vanessa</creatorcontrib><creatorcontrib>Chopin, Lucie</creatorcontrib><creatorcontrib>Roch, Emmanuelle</creatorcontrib><creatorcontrib>Gomez‐Escobar, Elsa</creatorcontrib><creatorcontrib>Roingeard, Philippe</creatorcontrib><title>Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B‐C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV‐HCV bivalent vaccine‐bearing genotype 1a HCV envelopes can induce neutralizing antibodies against this genotype, but is less effective against other genotypes. We show here, in a small animal model, that the use of a set of vaccine particles harbouring envelopes from different HCV genotypes in various association strategies can induce broad neutralizing protection or an optimized protection against a particular genotype prevalent in a given region, such as genotype 4 in Egypt. This vaccine could help to control the hepatitis C epidemic worldwide.</description><subject>Animal models</subject><subject>Antibodies</subject><subject>Disease control</subject><subject>Envelopes</subject><subject>Epidemics</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>HCV genetic variability</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>hepatitis B virus</subject><subject>Hepatitis C</subject><subject>hepatitis C virus</subject><subject>Life Sciences</subject><subject>Neutralizing</subject><subject>neutralizing antibodies</subject><subject>prophylactic vaccine</subject><subject>subviral envelope particles</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kc1uEzEUhS0EoqWw4AWQJTawSOu_iWeWbQSkUhAbyNbyz03ryhkH2xOYrrphzzPyJDhNCRIS3vja99M59j0IvaTklNZ1Fvz2lIpG0EfomArZTjjj9PGhZvwIPcv5hhDadQ19io44E03bEHmMfnz0331_hTc6FW8DZLxKcY23Ovk4ZDyfLfEV9LGMm9ryvU2gc63KNeD5xfLX3c8dsdXW-h6wNj74MuISMQRvfcEmRe3CiG2KOVe6h6EkHfztzlP3xZvoPOTn6MlKhwwvHvYT9OX9u8-z-WTx6cPl7HwxsYIxOgHTyUayaWdamDYWpHXSypZJKeuhk47Txq20Nc64llaWcEl0a2qfE5g6foLe7nWvdVCb5Nc6jSpqr-bnC7W7I4JS1nZ0Syv7Zs9uUvw6QC5q7bOFEHQPdTSKCSI5FdWloq__QW_ikPr6k0qxRtK2Y-Kv-f0wEqwOL6BE7XJUNUd1n2NlXz0oDmYN7kD-Ca4CZ3vgmw8w_l9JLS6Xe8nfsc2pVw</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Beaumont, Elodie</creator><creator>Joël Clément, Benoit</creator><creator>Guérin, Vanessa</creator><creator>Chopin, Lucie</creator><creator>Roch, Emmanuelle</creator><creator>Gomez‐Escobar, Elsa</creator><creator>Roingeard, Philippe</creator><general>Wiley Subscription Services, Inc</general><general>Wiley-Blackwell</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0001-9131-3341</orcidid></search><sort><creationdate>202008</creationdate><title>Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies</title><author>Beaumont, Elodie ; Joël Clément, Benoit ; Guérin, Vanessa ; Chopin, Lucie ; Roch, Emmanuelle ; Gomez‐Escobar, Elsa ; Roingeard, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4221-eb9757269b8e65ce7cd7c782777ce797d315dfacbdbd819750370a8b77730e6d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animal models</topic><topic>Antibodies</topic><topic>Disease control</topic><topic>Envelopes</topic><topic>Epidemics</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>HCV genetic variability</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>hepatitis B virus</topic><topic>Hepatitis C</topic><topic>hepatitis C virus</topic><topic>Life Sciences</topic><topic>Neutralizing</topic><topic>neutralizing antibodies</topic><topic>prophylactic vaccine</topic><topic>subviral envelope particles</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beaumont, Elodie</creatorcontrib><creatorcontrib>Joël Clément, Benoit</creatorcontrib><creatorcontrib>Guérin, Vanessa</creatorcontrib><creatorcontrib>Chopin, Lucie</creatorcontrib><creatorcontrib>Roch, Emmanuelle</creatorcontrib><creatorcontrib>Gomez‐Escobar, Elsa</creatorcontrib><creatorcontrib>Roingeard, Philippe</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beaumont, Elodie</au><au>Joël Clément, Benoit</au><au>Guérin, Vanessa</au><au>Chopin, Lucie</au><au>Roch, Emmanuelle</au><au>Gomez‐Escobar, Elsa</au><au>Roingeard, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2020-08</date><risdate>2020</risdate><volume>40</volume><issue>8</issue><spage>1865</spage><epage>1871</epage><pages>1865-1871</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B‐C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV‐HCV bivalent vaccine‐bearing genotype 1a HCV envelopes can induce neutralizing antibodies against this genotype, but is less effective against other genotypes. We show here, in a small animal model, that the use of a set of vaccine particles harbouring envelopes from different HCV genotypes in various association strategies can induce broad neutralizing protection or an optimized protection against a particular genotype prevalent in a given region, such as genotype 4 in Egypt. This vaccine could help to control the hepatitis C epidemic worldwide.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32458507</pmid><doi>10.1111/liv.14541</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-9131-3341</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2020-08, Vol.40 (8), p.1865-1871 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04112891v1 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Animal models Antibodies Disease control Envelopes Epidemics Genotype & phenotype Genotypes HCV genetic variability Hepatitis Hepatitis B hepatitis B virus Hepatitis C hepatitis C virus Life Sciences Neutralizing neutralizing antibodies prophylactic vaccine subviral envelope particles Vaccines Viruses |
| title | Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A19%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mixing%20particles%20from%20various%20HCV%20genotypes%20increases%20the%20HBV%E2%80%90HCV%20vaccine%20ability%20to%20elicit%20broadly%20cross%E2%80%90neutralizing%20antibodies&rft.jtitle=Liver%20international&rft.au=Beaumont,%20Elodie&rft.date=2020-08&rft.volume=40&rft.issue=8&rft.spage=1865&rft.epage=1871&rft.pages=1865-1871&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.14541&rft_dat=%3Cproquest_hal_p%3E2425718924%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425718924&rft_id=info:pmid/32458507&rfr_iscdi=true |